- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Report Discusses Trends of Psoriasis and Progress of the Global Psoriasis Atlas
Psoriasis has a significant presence, affecting about 125 million people globally, but current estimates are fragmented because of a lack of a global standard. A new report suggested that global data will need a standardized approach of collection and analysis in order for more accurate estimates of psoriasis’ presence.
Psoriasis has a significant presence, affecting about 125 million people globally, but current estimates are fragmented because of a lack of a global standard. A new report suggested that global data will need a standardized approach of collection and analysis in order for more accurate estimates of psoriasis’ presence.
The scientific report “Global State of Psoriasis Epidemiology: A Workshop Report” discusses the trends of psoriasis epidemiology and the progress of the web-based Global Psoriasis Atlas (GPA). It was curated after a workshop by the International Psoriasis Council (IPC) that consisted of global psoriasis experts. The main purpose of the workshop was to assess the current state of psoriasis epidemiology and GPA through a facilitated discussion on the overall health burden of psoriasis on the patient.
Darren Ashcroft, PhD, BPharm, MS, professor at the University of Manchester, emphasized the need for attention of the psoriasis health burden at the patient level. He also expressed the importance of analyzing genetic and environmental factors to determine their associations with cardiovascular disease.
"The data collected by the GPA will demonstrate to healthcare providers and policymakers around the world that psoriasis is not an inconsequential condition," Christopher Griffiths, MD, FRCP, professor at the University of Manchester, corresponding and first author of the report, IPC immediate past-president and GPA director, said in a statement. "The GPA will be a resource that will help improve treatment and patients' access to care worldwide and to recognize psoriasis as a healthcare priority."
The GPA was a main point of emphasis in the report as it was explained to be a long-term initiative that could provide a common standard for assessing the health burden of psoriasis globally. The GPA was established by the International League of Dermatological Societies and the International Federation of Psoriasis Associations.
The first phase of the GPA is expected to begin this year and will consist of global psoriasis data. The second phase will establish a standardized method for collecting future data from around the world.
“Ultimately, this resource is expected to drive improvement and equality of healthcare planning for psoriasis globally,” the report concluded.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More
